▶ Freely access a vast video library on NASH and NAFLD, its management and diagnosis along with the latest on pan-PPAR agonist, lanifibranor.
Nash Videos
Why are PPAR agonists a promising option for the management of NASH ?
Prof. Sven Francque, Chair of the PanNASH initiative reviews the current management options in NASH and the many molecules in development. It sheds light on the rationale for PPAR agonists as a promising and very valuable therapeutic option with systemic potential, for what happens in the liver and outside of the liver.
View More ⏩Why are PPAR agonists a promising option for the management of NASH ?Lipotoxicity in NASH
That’s a very important concept because lipotoxicity is…
Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASH
Discover the progresses of the quest for biomarkers in NASH with Prof Szabo
View More ⏩Prof Szabo Discusses the Progresses of the Quest of Biomarkers in NASHAn insight into the prevalence of NAFLD and NASH. Prof Abdelmalek, USA
Prevalence of NAFLD (non-alcoholic fatty liver disease) affects…
What are the current definitions ? Prof Abdelmalek, USA
So NAFLD (non-alcoholic fatty liver disease) is a…
Learn more about the burden of the disease, Prof Sven Francque, Belgium
June 12 is dedicated to increasing awareness about non-alcoholic steatohepatitis, or NASH, among various populations: the general public, at-risk patients, the medical community, public health authorities, and the media.
View More ⏩Learn more about the burden of the disease, Prof Sven Francque, BelgiumIs NASH only about the liver ?
Prof Jean-François Dufour, Switzerland sheds lights on this important question.
View More ⏩Is NASH only about the liver ?Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts
Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts presented in Boston during the Liver meeting 2019.
View More ⏩Prof Pierre-Emmanuel Rautou, Paris, France highlights two important abstracts